Inside IPEC–Americas: Excipient Audits and API Audits are Worlds Apart - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside IPEC–Americas: Excipient Audits and API Audits are Worlds Apart
The less complex nature of excipient manufacturers, as compared with API manufactures, carries many benefits.


Pharmaceutical Technology


Regulatory and cost benefits

In addition, GMP requirements for API manufacture are more explicit because of FDA requirements and guidelines from the International Conference on Harmonization. Official GMP requirements do not exist for excipients but standards are expressed in industry produced guidelines, whose application can vary greatly because of the range of processing involved. For example, the application of GMP standards for a salt producer that mines, purifies, and packages salt for use as an excipient would probably be very different from that of a synthetic excipient manufacturer.

There is one final significant difference between auditing excipient and API manufacturers. Because excipient manufacturers have numerous customers as compared with API manufacturers, it is feasible for excipient manufacturers to reduce audit assessment costs for their customers (and to themselves through a reduction in customer visits) by allowing the sharing of audit reports. It was for these reasons that IPEC–Americas formed its excipient GMP auditing subsidiary, International Pharmaceutical Excipients Auditing, Inc. (IPEA) in 2001 to assist excipient producers and their pharmaceutical customers. For example, the report of an IPEA third party audit requested by an excipient manufacturer can, if the company wishes, be shared with its potential customers. When this is publicized, it has served to reduce the number of new audit requests producers have received for up to two years after the IPEA audit.

Of note: An IPEC–China organization is being formed to join IPEC–Americas, IPEC–Europe and IPEC–Japan.Nevin Cheng of Shanghai Coating Technology, Ltd. will act as general manager for ongoing organizational efforts.

Irwin Silverstein, PhD, is vice-president of International Pharmaceutical Excipients Auditing Inc., the GMP auditing subsidiary of the International Pharmaceutical Excipients Council of the Americas. For more information, he can be contacted at


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here